Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

Lingg, G; Haushofer, A.
Clinical study comparing the effectiveness and tolerance of 2 current and one new glibenclamide formulation.
Wien Med Wochenschr. 1989; 139(12):281-284
Web of Science PubMed

Co-authors Med Uni Graz: Haushofer Alexander
Altmetrics:
Dimensions Citations:
Plum Analytics:
Abstract:: In a clinical study efficacy and tolerance of Neogluconin (2.5 mg) a new galenical form of glibenclamide were compared with a conventional preparation (Euglucon 5). Neogluconin showed an improved absorption and comparable blood sugar levels at a dosage reduced by 25%. 25 outpatients suffering from Type II diabetes in a well balanced metabolic state and previously under Euglucon therapy for at least one year were changed to the new product. After 2 months of Neogluconin therapy blood sugar profiles, HbA1, C-peptide and cholesterin levels were unchanged in comparison to values determined during the previous Euglucon treatment. This confirms that Neogluconin produces a comparable favorable blood glucose lowering effect despite a 25% reduction in dosage.
Find related publications in this database (using NLM MeSH Indexing): Aged -; Blood Glucose - metabolism; C-Peptide - blood; Clinical Trials as Topic -; Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy; Dose-Response Relationship, Drug -; Female -; Glyburide - administration and dosage Glyburide - therapeutic use; Hemoglobin A, Glycosylated - metabolism; Humans -; Male -; Middle Aged -; Prospective Studies -